Valuation: Valneva SE

Market Cap 413M 472M 381M 350M 663M 45.44B 675M 4.55B 1.78B 22.21B 1.77B 1.73B 76.55B P/E 2026 *
-5.93x
P/E 2027 * 5.73x
Enterprise Value 541M 619M 499M 459M 869M 59.53B 884M 5.96B 2.34B 29.09B 2.32B 2.27B 100B EV / Sales 2026 *
3.56x
EV / Sales 2027 * 1.61x
Free-Float
97.36%
Yield 2026 *
-
Yield 2027 * -
1 day+0.46%
1 week-4.37%
Current month-3.02%
1 month-4.04%
3 months-14.24%
6 months-50.16%
Current year-41.18%
1 week 2.15
Extreme 2.152
2.32
1 month 2.15
Extreme 2.152
2.37
Current year 2.14
Extreme 2.135
5.15
1 year 2.14
Extreme 2.135
5.42
3 years 1.73
Extreme 1.726
7.17
5 years 1.73
Extreme 1.726
29.7
10 years 1.73
Extreme 1.726
29.7
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 29/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 20/12/2023
Director/Board Member 75 07/03/2013
Chairman 65 20/12/2023
Date Insider Type Main position Quantity % Market Cap.
01-27Sell

Chief Technology Officer

11,800 0.0069%
01-26Sell

Chief Financial Officer

11,800 0.0069%
01-19Sell

Chief Operating Officer

34,355 0.0200%
Change 5-day change 1-year change 3-year change Capi.($)
+0.46%-4.37%-20.59%-67.60% 472M
-1.75%-2.06%+0.14%+5.43% 50.35B
-0.29%-2.81%+387.81%+591.82% 39.21B
-0.49%+1.48%+31.16%-6.46% 34.52B
+1.53%+3.11%+15.41%+58.54% 34.6B
+1.68%-0.62%+3.30%+27.34% 27.05B
+1.13%-3.11% - - 16.68B
-1.29%-0.52%+69.24%+117.60% 15.11B
-0.32%+0.41%+14.26%+17.60% 13.85B
+2.45%+3.99%+18.20%-30.12% 13.18B
Average +0.31%+0.38%+57.66%+79.35% 24.5B
Weighted average by Cap. +0.03%+0.82%+80.52%+120.93%

Financials

2026 *2027 *
Net sales 152M 174M 140M 129M 244M 16.71B 248M 1.67B 656M 8.17B 652M 638M 28.15B 294M 336M 271M 249M 472M 32.36B 481M 3.24B 1.27B 15.82B 1.26B 1.24B 54.52B
Net income -66.01M -75.5M -60.9M -55.98M -106M -7.27B -108M -727M -285M -3.55B -284M -277M -12.24B 70.5M 80.64M 65.04M 59.78M 113M 7.76B 115M 776M 305M 3.79B 303M 296M 13.07B
Net Debt 128M 146M 118M 109M 206M 14.09B 209M 1.41B 553M 6.89B 550M 538M 23.73B 60.02M 68.65M 55.37M 50.89M 96.43M 6.61B 98.08M 661M 259M 3.23B 258M 252M 11.13B
Logo Valneva SE
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
674
Date Price Change Volume
16/07/26 2.187 +0.46% 149,365
15/07/26 €2.177 -1.31% 325,463
14/07/26 €2.206 -2.82% 330,663
13/07/26 €2.270 +4.18% 572,226
10/07/26 €2.179 -4.72% 603,158
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.177EUR
Average target price
5.233EUR
Spread / Average Target
+140.39%

Quarterly revenue - Rate of surprise